Market capitalization | $1.70m |
Enterprise Value | $-9.23m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.47 |
P/B ratio (TTM) P/B ratio | 0.13 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-6.89m |
Free cash flow (TTM) Free cash flow | $-6.27m |
Cash position | $10.93m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:
1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:
Dec '23 | |
Current assets | 13 13 |
Fixed assets | 3.39 3.39 |
Total assets | 17 17 |
Dec '23 | |
Equity | 14 14 |
Debt capital | 2.75 2.75 |
Total capital | 17 17 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Head office | Israel |
CEO | Allen Baharaff |
Employees | 8 |
Founded | 2000 |
Website | galmedpharma.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.